The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Carla M. L. van Herpen

Department of Oncology

Radboud University Nijmegen Medical Centre




Name/email consistency: high



  • Department of Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. 2004 - 2013


  1. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. van Herpen, C.M., Lassen, U., Desar, I.M., Brown, K.H., Marotti, M., de Jonge, M.J. Anticancer. Drugs (2013) [Pubmed]
  2. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. van Herpen, C.M., Eskens, F.A., de Jonge, M., Desar, I., Hooftman, L., Bone, E.A., Timmer-Bonte, J.N., Verweij, J. Br. J. Cancer (2010) [Pubmed]
  3. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). van Herpen, C.M., Mauer, M.E., Mesia, R., Degardin, M., Jelic, S., Coens, C., Betka, J., Bernier, J., Remenar, E., Stewart, J.S., Preiss, J.H., van den Weyngaert, D., Bottomley, A., Vermorken, J.B. Br. J. Cancer (2010) [Pubmed]
  4. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). van Herpen, C.M., Locati, L.D., Buter, J., Thomas, J., Bogaerts, J., Lacombe, D., de Mulder, P., Awada, A., Licitra, L., Bernier, J., Vermorken, J.B. Eur. J. Cancer (2008) [Pubmed]
  5. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. van Herpen, C.M., van der Voort, R., van der Laak, J.A., Klasen, I.S., de Graaf, A.O., van Kempen, L.C., de Vries, I.J., Boer, T.D., Dolstra, H., Torensma, R., van Krieken, J.H., Adema, G.J., De Mulder, P.H. Int. J. Cancer (2008) [Pubmed]
  6. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. van Herpen, C.M., van der Laak, J.A., de Vries, I.J., van Krieken, J.H., de Wilde, P.C., Balvers, M.G., Adema, G.J., De Mulder, P.H. Clin. Cancer Res. (2005) [Pubmed]
  7. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1. van Herpen, C.M., Bussink, J., van der Kogel, A.J., Peeters, W.J., van der Voort, R., van Schijndel, A., de Wilde, P.C., Adema, G.J., de Mulder, P.H. Anticancer Res. (2005) [Pubmed]
  8. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. van Herpen, C.M., Looman, M., Zonneveld, M., Scharenborg, N., de Wilde, P.C., van de Locht, L., Merkx, M.A., Adema, G.J., de Mulder, P.H. Clin. Cancer Res. (2004) [Pubmed]
WikiGenes - Universities